Jeff Yass’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-89,900
| Closed | -$1.81M | – | 13988 |
|
|
2026
Q1 | $1.81M | Buy |
89,900
+36,200
| +67% | +$583K | ﹤0.01% | 6401 |
|
|
2025
Q4 | $867K | Buy |
53,700
+41,800
| +351% | +$554K | ﹤0.01% | 7505 |
|
|
2025
Q3 | $145K | Sell |
11,900
-258,700
| -96% | -$3.57M | ﹤0.01% | 11307 |
|
|
2025
Q2 | $3.06M | Sell |
270,600
-66,800
| -20% | -$817K | ﹤0.01% | 4924 |
|
|
2025
Q1 | $3.89M | Buy |
+337,400
| New | +$3.44M | ﹤0.01% | 4124 |
|
|
2024
Q3 | – | Sell |
-12,500
| Closed | -$147K | – | 12523 |
|
|
2024
Q2 | $147K | Sell |
12,500
-35,000
| -74% | -$408K | ﹤0.01% | 10712 |
|
|
2024
Q1 | $563K | Sell |
47,500
-240,700
| -84% | -$3.21M | ﹤0.01% | 8229 |
|
|
2023
Q4 | $3.53M | Buy |
288,200
+164,900
| +134% | +$1.5M | ﹤0.01% | 4308 |
|
|
2023
Q3 | $1.19M | Buy |
123,300
+91,700
| +290% | +$937K | ﹤0.01% | 6251 |
|
|
2023
Q2 | $284K | Buy |
+31,600
| New | +$291K | ﹤0.01% | 9550 |
|
|
2022
Q4 | – | Sell |
-96,100
| Closed | -$1.39M | – | 13062 |
|
|
2022
Q3 | $1.39M | Sell |
96,100
-1,400
| -1% | -$19.6K | ﹤0.01% | 5759 |
|
|
2022
Q2 | $959K | Buy |
97,500
+59,400
| +156% | +$655K | ﹤0.01% | 6636 |
|
|
2022
Q1 | $562K | Buy |
+38,100
| New | +$547K | ﹤0.01% | 8681 |
|
|
2021
Q4 | – | Sell |
-10,000
| Closed | -$175K | – | 13511 |
|
|
2021
Q3 | $175K | Sell |
10,000
-34,800
| -78% | -$705K | ﹤0.01% | 11638 |
|
|
2021
Q2 | $1.07M | Sell |
44,800
-16,100
| -26% | -$421K | ﹤0.01% | 7572 |
|
|
2021
Q1 | $1.56M | Buy |
60,900
+13,200
| +28% | +$347K | ﹤0.01% | 6523 |
|
|
2020
Q4 | $906K | Buy |
+47,700
| New | +$818K | ﹤0.01% | 6943 |
|
Other funds holding KALV
Jeff Yass's KALV Position: Q2 2026 in Review
Jeff Yass sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 46,760 shares — an estimated $941K sold.
Jeff Yass first reported a position in KALV in Q2 2016 and held it in 24 quarters. The position peaked at $4.79M in Q3 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Jeff Yass reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 46,760 KalVista Pharmaceuticals shares in Q2 2026, an estimated $941K.
- Jeff Yass first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 24 quarters.
- Jeff Yass's KalVista Pharmaceuticals position peaked at $4.79M in Q3 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.